With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let’s have a look at some of the rulings, studies, and companies that made waves in the sector last week.
Last week was dominated by a mountain of data coming out of the American Society of Clinical Oncology’s annual meeting in Chicago. In fact, there was so much information to plow through that, in a separate article, I discussed the five most important and intriguing studies unveiled at ASCO. I encourage you to review that article to get an idea on what disease treatments were in high demand this year.
Having covered the goings-on at ASCO already, I propose we look at five additional newsworthy stories this week in the biotech sector.
On Wednesday, Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) received good news from the Food and Drug Administration, which OK’d an accelerated development pathway for pre-investigational neuropathic pain drug AVP-786. The accelerated approval was based on data from AVP-923 and will allow Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) to conduct minimal preclinical testing before advancing onto human trials. This saves the company time and, more importantly, precious cash. I would, however, caution against getting too excited, as even this accelerated development puts this drug, which isn’t even in clinical trials yet, years away from a possible approval.
You can also chalk up an early week win for Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and its homozygous familial hypercholesterolemia, or HoFH, drug known as Juxtapid. The drug, which is known as Lojuxta in Europe, received a positive opinion from the Committee for Medicinal Products for Human Use and is poised to get a decision on approval from the European Medicines Agency sometime in the third quarter. In the U.S. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) recently announced plans to boost the annual price on its breakthrough pill from $235,000 to $295,000, but consider me still not fully sold that this will be enough to justify Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s insane share price spike or even get the company solidly into the black.
It wasn’t nearly as exciting a week for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), which regained full rights to rheumatoid arthritis pill Fostamatinib from AstraZeneca plc (ADR) (NYSE:AZN) on Tuesday. The pair actually reported a statistically significant ACR20 response rate at 24 weeks in two trials, but the data isn’t expected to be conclusive enough to gain FDA approval. AstraZeneca, not wanting to spend any more on the program, took a $140 million charge and returned all licensing back to Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). With the prospect of high trial costs and a drug which did well, but perhaps not well enough to compete with competition already on the market, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is now in a tough position and is worth avoiding at all costs.
